Physician profile
Matthew Ingham
NPI 1538485719
$14,658.53
in general payments reported to CMS, 2019-2025
21 companies · $15.11 in 2025
The $15.11 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,856 · 2020: $8,403 · 2021: $1,072 · 2022: $3,286 · 2023: $25.46 · 2025: $15.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $40.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $40.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $8,212.99 | 2020 | |
| Ptc Therapeutics, INC. | $3,254.80 | 2022 | |
| F. Hoffmann-La Roche Ag | $1,707.19 | 2019 | |
| Boehringer Ingelheim International Gmbh | $968.19 | 2021 | |
| Boehringer Ingelheim Pharma Gmbh & Co.Kg | $190.36 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $148.80 | 2019 | |
| Abbott Laboratories | $104.06 | 2021 | |
| Seagen INC. | $31.57 | 2022 | |
| Emd Serono, INC. | $25.46 | 2023 | Bavencio |
| Procept Biorobotics Corporation | $15.11 | 2025 |
11 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Ingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.